Cardiometabolic disease treatments and biotech innovation by Esperion Therapeutics

Esperion Therapeutics has announced an active hiring campaign aimed at enhancing its position in the field of cardiovascular care. The company is encouraging candidates to explore new employment ...

Esperion Therapeutics unveiled data from its CLEAR Outcomes trial and the CLEAR PATH Phase 2 pediatric study at the European Atherosclerosis Society Congress 2026. The presentations focused on ...

Esperion Therapeutics estimates the annual economic burden of heart failure in the U.S. at 46 billion dollars, encompassing healthcare services, medications, and lost productivity. The company ...

Esperion Therapeutics announced that it will release its financial results for the first quarter of 2026 on May 7. This upcoming report is expected to provide insights into the company’s ...

Esperion Therapeutics draws attention to the recently released 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia. The discussion featured Dr. Steve Nissen and Dr. C. Michael ...

Esperion Therapeutics asserts that hsCRP is an important biomarker for identifying residual inflammatory risk, even for patients who have met LDL-C targets. The company recommends integrating ...

Esperion Therapeutics has been recognized in the Health Care and Life Sciences category of the Financial Times Americas’ Fastest Growing Companies list for 2026. The company achieved a ranking ...

Esperion Therapeutics will participate in the 25th Annual Needham Virtual Healthcare Conference. The event brings together leading companies and investors in the healthcare sector. Participation ...

Esperion Therapeutics presented new findings from its CLEAR Outcomes study, focusing on the value of its cholesterol-lowering therapy NEXLETOL (bempedoic acid), at the American College of ...

Esperion Therapeutics will present two new analyses from its CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session. The company aims to showcase the ...

Esperion Therapeutics has reached a definitive agreement to acquire Corstasis Therapeutics, marking a strategic move to expand its cardiovascular franchise. The deal will add Enbumyst, a ...

Esperion Therapeutics is raising concerns over the potential for increased cholesterol levels during the colder months. Research indicates that low-density lipoprotein cholesterol (LDL-C) tends to ...

Esperion Therapeutics is gearing up for the 2026 J.P. Morgan Healthcare Conference by looking to present its latest preliminary results from 2025 and unveil a strategic roadmap aimed at long-term ...

Esperion Therapeutics has announced its participation in the Jefferies Global Healthcare Conference in London. This move signals the company's engagement in key industry events. The conference is ...

Esperion Therapeutics is renewing its commitment to tackling primary sclerosing cholangitis (PSC), a disease affecting thousands of individuals in the U.S. and Europe. With no currently approved ...